Concepedia

Douglas O. Escrivani

DO

Statistics

Publications

6

Citations

110

H-Index

6

Active since

2018

Affiliations

Universidade Federal do Rio de Janeiro(Current)

Durham University

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Douglas O. Escrivani is an author at Universidade Federal do Rio de Janeiro specializing in antileishmanial treatment, pharmacology, and pharmacy.

ORCID

Publications per year

2018–2021

6

Publications

6

Chalcones identify cTXNPx as a potential antileishmanial drug target

Douglas O. Escrivani, Rebecca L. Charlton, Marjolly B. Caruso et al. · PLoS neglected tropical diseases · 2021 · 34 citations · Full text

, , +17

Antileishmanial Chemotherapy through Clemastine Fumarate Mediated Inhibition of the <i>Leishmania</i> Inositol Phosphorylceramide Synthase

John G. Mina, Rebecca L. Charlton, Edubiel A. Alpizar-Sosa et al. · ACS Infectious Diseases · 2020 · 24 citations · Full text

, , +17

Broad Spectrum and Safety of Oral Treatment with a Promising Nitrosylated Chalcone in Murine Leishmaniasis

Ariane J. Sousa-Batista, Douglas O. Escrivani, Camila Alves Bandeira Falcão et al. · Antimicrobial Agents and Chemotherapy · 2018 · 16 citations · Full text

, , +17

Single-dose treatment for cutaneous leishmaniasis with an easily synthesized chalcone entrapped in polymeric microparticles

Ariane J. Sousa-Batista, Natalia Arruda-Costa, Douglas O. Escrivani et al. · Parasitology · 2020 · 14 citations · Full text

, , +17

Encapsulation in lipid-core nanocapsules improves topical treatment with the potent antileishmanial compound CH8

Douglas O. Escrivani, Milene V. Lopes, Fernanda Poletto et al. · Nanomedicine Nanotechnology Biology and Medicine · 2019 · 12 citations · Full text

, , +16

1–5 of 6